Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

被引：0
作者：
Andrew M. Blumenfeld
Richard J. Stark
Marshall C. Freeman
Amelia Orejudos
Aubrey Manack Adams
机构：
[1] The Neurology Center,Headache Center of Southern California
[2] Monash University and Alfred Hospital,undefined
[3] Headache Wellness Center,undefined
[4] Allergan plc,undefined
来源：
The Journal of Headache and Pain | 2018年 / 19卷
关键词：
OnabotulinumtoxinA; Efficacy; Safety; Long-term; Chronic migraine; Prophylaxis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [1] Lipton RB(2013)The international classification of headache disorders, 3rd edition (beta version) Cephalalgia 33 629-808
  • [2] Varon SF(2011)OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine Neurology 77 1465-1472
  • [3] Grosberg B(2016)Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study Mayo Clin Proc 91 596-611
  • [4] McAllister PJ(2008)Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment Neurology 71 559-566
  • [5] Freitag F(2011)OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program Headache 51 1358-1373
  • [6] Aurora SK(2010)OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program Headache 50 921-936
  • [7] Dodick DW(2006)Prophylaxis of migraine Neuropsychiatr Dis Treat 2 281-291
  • [8] Silberstein SD(undefined)undefined undefined undefined undefined-undefined
  • [9] Diener HC(undefined)undefined undefined undefined undefined-undefined
  • [10] DeGryse RE(undefined)undefined undefined undefined undefined-undefined
12345